Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
about
Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantationHigh-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastomaHigh-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastomaHigh-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastomaNeuroblastoma: issues in transplantationA focal lesion in the falx cerebri: Harbinger of classic stage 4 neuroblastoma in an infant cured despite residual disease after minimal therapy.Locoregional tumor progression after radiation therapy influences overall survival in pediatric patients with neuroblastoma.Treatment results and prognostic factors of pediatric neuroblastoma: a retrospective study28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures.Reverse engineering the neuroblastoma regulatory network uncovers MAX as one of the master regulators of tumor progression.Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age.Mechanisms of CHD5 Inactivation in neuroblastomas.Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells.Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy.Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers.Immunology and immunotherapy of neuroblastomaClinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma.Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastomaSIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settingsOptimization of a Neural Stem-Cell-Mediated Carboxylesterase/Irinotecan Gene Therapy for Metastatic Neuroblastoma.Pharmacotherapy of neuroblastoma.Neuroblastoma: the impact of biology and cooperation leading to personalized treatments.Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation.Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors.Targeting of heme oxygenase-1 as a novel immune regulator of neuroblastoma.Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution.A single center clinical analysis of children with neuroblastoma.Residual tumor in cases of intermediate-risk neuroblastoma did not influence the prognosis.Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology GroupThe International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.Low NDRG1 mRNA expression predicts a poor prognosis in neuroblastoma patients.Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification.Early therapy-related myeloid sarcoma and deletion of 9q22.32 to q31.1.Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.Excellent treatment outcomes in children younger than 18 months with stage 4 MYCN nonamplified neuroblastoma.
P2860
Q24186451-370422D7-80C7-4EC9-A0FB-79B82F083408Q24186636-0A466FDE-5F37-475F-AF57-0476FBA12B2EQ24200296-047BF2B4-FAEE-403E-95C1-3EC6BCAE3809Q24235309-2E5A5D5D-0D13-4050-B459-B3973A23EC63Q27008197-06B78655-0DCE-4D0D-89D8-7AA9F63327C9Q33836071-74FE23DE-1EAC-4C95-BE23-67BAB7A8FC3AQ33908476-5028470F-A94A-4733-A07C-11720508CC9FQ34477899-BDE8D840-137D-4A2F-BC74-9A0352A62B06Q34785880-871B4649-0653-4460-9199-65869CB7950FQ35070297-51938D7E-9B65-464C-BF63-BEC5D07E0010Q35565637-CE24F62F-8549-4728-B72B-9FEF60932CF7Q35836491-C3EA0B2C-EF1E-4573-8368-02CF0BEFC15FQ36276185-D65F572A-55AB-4826-8627-E73D0865B0ADQ36294761-68FC0D3B-AAEF-4D8E-85E4-8F6C575CB238Q36378134-BCC6C68C-35FF-49E9-A090-FF589B3F9C67Q36856798-D8766333-F8B6-4040-98D2-B75DEC8B948AQ36910335-CF47229B-EE69-4F8D-BA7A-7DACF55A3B22Q37078231-73D8C3C3-3A8B-4D76-8E9C-38EF041C7219Q37461968-FC9B9B92-B4B3-437C-A37F-A78F49FDAB3FQ37718554-AB17728A-E1A5-4E39-8886-1DB5CABD4DADQ37735199-FE310ECB-B278-4691-8A63-A6C598737F50Q38014527-9BF48567-A53D-4A6E-8A17-DD99E4BD148BQ38608663-6E86CA81-72BD-4F4D-B0F0-CB04661A767EQ38702196-20627C47-365B-48B5-A44D-A15A1F60D959Q38817604-FDE05B5C-6D13-4787-A9F9-6A709A04B7DCQ38886708-CF080629-8A67-43F7-82B7-23B50092D430Q39865674-C1C7911C-9E70-4567-867F-F128D92E3751Q40257611-60328488-9F74-43B7-BE87-36B706E4936CQ40743437-96603748-3D5A-4BFE-9C5E-D6AA449DB697Q41842569-2B1E92A2-D0DF-4B07-935A-0529F95CBE89Q41883212-8FE092ED-44C9-4CC8-BEF2-6FD7F1EC19CEQ44377152-AE5E6F2A-6BE5-4E28-B759-4744082ECB38Q46527475-3F32EB1E-3266-49DF-B73C-5B29E256CDBFQ50674980-B28374EB-55B6-45A7-AD4A-1B3B41E23846Q51528452-8E217F18-4E99-414B-9C2C-731D8AC859FCQ55127179-5E5AD8F3-6D5F-41EA-A241-AD94B0090B15
P2860
Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Favorable prognosis for patien ...... Children's Cancer Group Study.
@ast
Favorable prognosis for patien ...... Children's Cancer Group Study.
@en
Favorable prognosis for patien ...... Children's Cancer Group Study.
@nl
type
label
Favorable prognosis for patien ...... Children's Cancer Group Study.
@ast
Favorable prognosis for patien ...... Children's Cancer Group Study.
@en
Favorable prognosis for patien ...... Children's Cancer Group Study.
@nl
prefLabel
Favorable prognosis for patien ...... Children's Cancer Group Study.
@ast
Favorable prognosis for patien ...... Children's Cancer Group Study.
@en
Favorable prognosis for patien ...... Children's Cancer Group Study.
@nl
P2093
P356
P1476
Favorable prognosis for patien ...... Children's Cancer Group Study.
@en
P2093
Ashutosh Lal
Hiroyuki Shimada
John M Maris
Katherine K Matthay
Mary Lou Schmidt
Maura O'Leary
Robert B Gerbing
Robert C Seeger
P304
P356
10.1200/JCO.2005.05.183
P407
P577
2005-08-22T00:00:00Z